Remedium Lifecare Kicks Off FY26 with ?464.88 Lakh PAT in Q1, Surpassing and Doubling FY25 Profit and Driving Expansion Plans
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Remedium Lifecare Ltd reported a Profit After Tax of ₹464.88 lakhs for Q1 FY26 (quarter ended June 30, 2025), a sharp turnaround from a loss of ₹204.60 lakhs in the previous quarter (Q4 FY25). This single-quarter profit is more than double the company's entire FY25 PAT of ₹212.94 lakhs. Revenue from operations for the quarter stood at ₹11,336.67 lakhs, with Profit Before Tax reaching ₹571.23 lakhs. The company attributed the performance to effective cost management and improved operational efficiencies. Management highlighted plans to expand R&D focus in anti-infectives, cardiovascular, and CNS therapeutic areas, build CDMO capabilities, and pursue international market expansion. Note: the filing was submitted under the name Supha Pharmachem Ltd but the document content pertains to Remedium Lifecare Ltd.
A strong Q1 turnaround that already exceeds the prior full-year profit signals a meaningful improvement in earnings momentum, which could be positive for the stock. However, the optimism around R&D and international expansion is forward-looking and execution-dependent, so investors should watch for confirmation in upcoming quarters.